Taisho Pharmaceutical Co. said Tuesday it will discontinue the development of a new oral drug for chronic asthma because unwanted side effects occurred in U.S. clinical tests.

The drug was found clinically effective, but three patients experienced elevations in liver enzymes that were likely related to the drug, Japan’s top over-the-counter drugmaker said in a statement.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.